LEO Pharma A/S, a global leader in medical dermatology, today announced it has appointed Brian Hilberdink new Executive Vice President and President of LEO Pharma Inc. in the United States, effective
LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022. Tralokinumab is marketed outside of the U.S. under the
LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab) .